SCHEMBL2594606

SCHEMBL2594606

NC(=O)Cn1ncc2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.59
POLB P06746 4/20 0.53
RECQL P46063 2/20 0.53
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
TSHR P16473 3/20 0.52
HSD17B10 Q99714 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
CYP1A2 P05177 1/20 0.49
KDM4E B2RXH2 1/20 0.47
MAPK1 P28482 1/20 0.47
LMNA P02545 1/20 0.45
DAO P14920 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374171 0.84 KMO (0.71) KMOPOLBRECQLNPC1RAB9A
SCHEMBL29544889 0.84 KMO (0.71) KMOPOLBRECQLNPC1RAB9A
SCHEMBL8889255 0.83 KMO (0.74) KMOPOLBRECQLNPC1RAB9A
SCHEMBL27733623 0.83 NPC1 (0.56) KMOPOLBRECQLNPC1RAB9A
SCHEMBL8999792 0.83 KMO (0.59) KMOPOLBRECQLNPC1RAB9A
SCHEMBL28736790 0.82 KMO (0.68) KMOPOLBRECQLNPC1RAB9A
SCHEMBL38656843 0.82 NPC1 (0.59) KMOPOLBRECQLNPC1RAB9A
SCHEMBL27733621 0.81 NPC1 (0.54) KMOPOLBRECQLNPC1RAB9A
SCHEMBL13978502 0.80 KMO (0.43) KMOPOLBRECQLNPC1RAB9A
SCHEMBL12892436 0.80 POLB (0.56) KMOPOLBRECQLNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110396089-A Target compound and the application of kidney type glutaminase allosteric site HANGZHOU JIANNIFU BIOLOGICAL TECH CO LTD 2019-11-01 CN claimed
WO-2011138265-A2 INDOLE AND INDAZOLE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS EVOTEC AG (DE) 2011-11-10 WO claimed
CN-111590988-B Processing method of NY/RCPP composite film for high-temperature steaming bag 合肥佛斯德新材料科技有限公司 2022-04-01 CN disclosed
CN-111590988-A Processing method of NY/RCPP composite film for high-temperature steaming bag 合肥佛斯德新材料科技有限公司 2020-08-28 CN disclosed
CN-110396089-A Target compound and the application of kidney type glutaminase allosteric site HANGZHOU JIANNIFU BIOLOGICAL TECH CO LTD 2019-11-01 CN disclosed
US-8648076-B2 Cysteine protease inhibitors and their therapeutic applications HYBRIGENICS SA (FR) 2014-02-11 US disclosed
CN-102260214-B Method for preparing indazole compound UNIV ZHEJIANG 2013-12-04 CN disclosed
CN-102260214-B Method for preparing indazole compound UNIV ZHEJIANG 2013-12-04 CN disclosed
CN-101747277-B Application and preparation of indazole compound UNIV ZHEJIANG 2012-01-25 CN disclosed
CN-101747277-B Application and preparation of indazole compound UNIV ZHEJIANG 2012-01-25 CN disclosed
CN-102260214-A Method for preparing indazole compound 2011-11-30 CN disclosed
CN-101747277-A Application and preparation of indazole compound UNIV ZHEJIANG 2010-06-23 CN disclosed
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US disclosed
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US disclosed
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US disclosed
US-20090215786-A1 NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2009-08-27 US disclosed
CN-101189241-A Thienopyridine derivative, quinoline derivative, and quinazoline derivative having c-Met autophosphorylation inhibiting activity KIRIN PHARMA KK (JP) 2008-05-28 CN disclosed
EP-1870414-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY Kirin Pharma Kabushiki Kaisha (JP) 2007-12-26 EP disclosed
US-20070032499-A1 Novel cysteine protease inhibitors and their therapeutic applications HYBRIGENICS SA (FR) 2007-02-08 US disclosed
WO-2007008514-A2 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 GEORGETOWN UNIVERSITY (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032499-A1 Novel cysteine protease inhibitors and their therapeutic applications SERPINB1, CTSF, CTSE KMO 4653/4885POLB 4100/4885RECQL 3852/4885
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY MET, ABL1, RET KMO 1635/4885POLB 4415/4885RECQL 1287/4885
US-20090215786-A1 NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS SERPINB1, CTSF, CTSE KMO 4653/4885POLB 4100/4885RECQL 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.